SYNLAB And Microba Advance Partnership With Latest-Generation Microbiome Testing

SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences have entered into a new three-year agreement to advance their partnership in microbiome diagnostics across selected markets in Europe and Latin America.

Building on a partnership established in 2020, the new agreement marks the transition from Microba’s legacy Insight test to its latest-generation clinical-grade Microbiome Explorer platform. The platform will be integrated into SYNLAB’s diagnostic offering and digital systems, enabling SYNLAB to make the upgraded microbiome testing solution available to healthcare professionals and patients across its network.

The next phase of the partnership combines Microba’s leading expertise in microbiome analysis with SYNLAB’s medical excellence, diagnostic capabilities and established healthcare network.

Through this upgrade, Microba and SYNLAB aim to support access to advanced microbiome insights and further develop their microbiome diagnostics offering across Europe and Latin America.

About SYNLAB

• SYNLAB Group is a leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporations.
• Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
• SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 23,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
• SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.54B in 2025.
• For more information, visit www.synlab.com